Valupak Vitamin D3 5000IU Tablets 30’s
Review By MIYINGO Ivan, B. Pharm, MPS.
1. Product Name
Valupak Vitamin D3 5000IU Tablets 30’s
Generic Name: Cholecalciferol (Vitamin D3)
Dosage Form: Film-coated tablet
Strength: 5000 International Units (IU) per tablet
Pack Size: 30 tablets per blister pack
2. Composition
Ingredient Amount per Tablet Role Cholecalciferol (Vitamin D3) 5000 IU Active ingredient; supports calcium absorption, bone health, and immune function Microcrystalline cellulose q.s. Binder/filler Sodium starch glycolate q.s. Disintegrant Magnesium stearate q.s. Lubricant Hypromellose q.s. Tablet coating Titanium dioxide q.s. Opacifier/colorant Lactose monohydrate q.s. Filler
| Ingredient | Amount per Tablet | Role |
|---|---|---|
| Cholecalciferol (Vitamin D3) | 5000 IU | Active ingredient; supports calcium absorption, bone health, and immune function |
| Microcrystalline cellulose | q.s. | Binder/filler |
| Sodium starch glycolate | q.s. | Disintegrant |
| Magnesium stearate | q.s. | Lubricant |
| Hypromellose | q.s. | Tablet coating |
| Titanium dioxide | q.s. | Opacifier/colorant |
| Lactose monohydrate | q.s. | Filler |
Excipients are pharmaceutically inactive but essential for tablet stability, release, and patient compliance.
3. Pharmacological Properties
3.1. Pharmacodynamics
Vitamin D3 (Cholecalciferol) is a fat-soluble secosteroid essential for calcium and phosphorus homeostasis. It is metabolized in the liver to 25-hydroxyvitamin D (calcidiol) and then in the kidneys to 1,25-dihydroxyvitamin D (calcitriol), the biologically active form.
-
Enhances intestinal absorption of calcium and phosphorus.
-
Regulates bone mineralization and remodeling.
-
Modulates immune system activity, contributing to both innate and adaptive immunity.
-
Supports normal muscle function and cellular growth and differentiation.
3.2. Pharmacokinetics
-
Absorption: Rapidly absorbed in the small intestine with dietary fat; peak plasma levels occur within 12–24 hours.
-
Distribution: Highly lipophilic; stored in liver, adipose tissue, and muscle.
-
Metabolism: Converted in the liver to 25-hydroxycholecalciferol (calcidiol) and then in kidneys to 1,25-dihydroxycholecalciferol (calcitriol).
-
Elimination: Half-life of 25-hydroxycholecalciferol ~15 days; excreted primarily in bile and feces.
Absorption: Rapidly absorbed in the small intestine with dietary fat; peak plasma levels occur within 12–24 hours.
Distribution: Highly lipophilic; stored in liver, adipose tissue, and muscle.
Metabolism: Converted in the liver to 25-hydroxycholecalciferol (calcidiol) and then in kidneys to 1,25-dihydroxycholecalciferol (calcitriol).
Elimination: Half-life of 25-hydroxycholecalciferol ~15 days; excreted primarily in bile and feces.
4. Indications
-
Prevention and treatment of vitamin D deficiency.
-
Support of bone health, particularly in adults at risk of osteoporosis or osteomalacia.
-
Adjunct therapy for calcium supplementation.
-
Maintenance of normal immune system function.
-
Individuals with limited sun exposure or malabsorption syndromes.
Prevention and treatment of vitamin D deficiency.
Support of bone health, particularly in adults at risk of osteoporosis or osteomalacia.
Adjunct therapy for calcium supplementation.
Maintenance of normal immune system function.
Individuals with limited sun exposure or malabsorption syndromes.
5. Dosage and Administration
-
Adults: 1 tablet (5000 IU) daily, preferably with food to enhance absorption.
-
Duration: As prescribed by a healthcare provider; typically short-term correction of deficiency or as maintenance in high-risk patients.
-
Special Populations:
-
Elderly: Same dose, monitor serum vitamin D levels.
-
Renal impairment: Monitor calcium and vitamin D levels.
-
Pregnancy/lactation: Only if indicated by a physician; avoid excessive dosing.
Adults: 1 tablet (5000 IU) daily, preferably with food to enhance absorption.
Duration: As prescribed by a healthcare provider; typically short-term correction of deficiency or as maintenance in high-risk patients.
Special Populations:
-
Elderly: Same dose, monitor serum vitamin D levels.
-
Renal impairment: Monitor calcium and vitamin D levels.
-
Pregnancy/lactation: Only if indicated by a physician; avoid excessive dosing.
Do not exceed recommended dosage to prevent hypervitaminosis D.
6. Contraindications
-
Hypercalcemia or hypervitaminosis D.
-
Severe renal impairment without supervision.
-
Known hypersensitivity to vitamin D3 or any excipients.
Hypercalcemia or hypervitaminosis D.
Severe renal impairment without supervision.
Known hypersensitivity to vitamin D3 or any excipients.
7. Warnings and Precautions
-
Excessive intake may cause hypercalcemia, hypercalciuria, and soft tissue calcification.
-
Patients with sarcoidosis, tuberculosis, or other granulomatous diseases should use cautiously.
-
Monitor serum calcium and vitamin D levels during prolonged use.
-
Not a substitute for a balanced diet and sunlight exposure.
Excessive intake may cause hypercalcemia, hypercalciuria, and soft tissue calcification.
Patients with sarcoidosis, tuberculosis, or other granulomatous diseases should use cautiously.
Monitor serum calcium and vitamin D levels during prolonged use.
Not a substitute for a balanced diet and sunlight exposure.
8. Drug Interactions
-
Corticosteroids: May reduce vitamin D activity.
-
Orlistat and cholestyramine: May decrease absorption.
-
Thiazide diuretics: Risk of hypercalcemia increases.
-
Anticonvulsants (e.g., phenytoin, phenobarbital): May increase vitamin D metabolism, reducing efficacy.
Corticosteroids: May reduce vitamin D activity.
Orlistat and cholestyramine: May decrease absorption.
Thiazide diuretics: Risk of hypercalcemia increases.
Anticonvulsants (e.g., phenytoin, phenobarbital): May increase vitamin D metabolism, reducing efficacy.
9. Adverse Effects
Generally well tolerated; adverse effects are rare at recommended doses:
-
Mild: Constipation, nausea, stomach discomfort.
-
Moderate: Hypercalcemia (fatigue, headache, polyuria).
-
Severe (rare, usually with overdose): Kidney stones, vascular calcification, arrhythmias.
10. Overdose
-
Symptoms: Hypercalcemia, nausea, vomiting, polyuria, dehydration, kidney damage.
-
Management: Discontinue supplement, supportive therapy, hydration, monitoring of calcium and renal function.
Symptoms: Hypercalcemia, nausea, vomiting, polyuria, dehydration, kidney damage.
Management: Discontinue supplement, supportive therapy, hydration, monitoring of calcium and renal function.
11. Storage
-
Store at 20–25°C (room temperature).
-
Protect from moisture, heat, and light.
-
Keep out of reach of children.
Store at 20–25°C (room temperature).
Protect from moisture, heat, and light.
Keep out of reach of children.
12. Shelf Life
-
Typically 24 months from date of manufacture.
Typically 24 months from date of manufacture.
13. Pharmaceutical Packaging
-
Blister pack of 30 tablets per box.
-
Each tablet: Film-coated, white to off-white, round.
-
Packaging designed to maintain stability and prevent moisture ingress.
Blister pack of 30 tablets per box.
Each tablet: Film-coated, white to off-white, round.
Packaging designed to maintain stability and prevent moisture ingress.
14. Regulatory Status
-
Classified as a dietary supplement / vitamin preparation.
-
May require local registration depending on country regulations.
Classified as a dietary supplement / vitamin preparation.
May require local registration depending on country regulations.
AUTHOR
MIYINGO Ivan
B. Pharm, MPS
+256700991510
miyingoivan@gmail.com

Comments
Post a Comment